Characteristics of 120 hospitalised patients with SARS-CoV-2 infection in Wuhan
| Characteristic | Total patients | Days to negativity | p-value# | |
| ≤23 | >23 | |||
| Patients | 120 | 61 | 59 | |
| Age years | 52 (35–63) | 48 (33–60) | 56 (42–65) | 0.04 |
| Male sex | 54 (45) | 30 (49.2) | 24 (40.7) | 0.35 |
| Current smoker | 12 (10) | 5 (8.2) | 7 (11.9) | 0.50 |
| Comorbidity | ||||
| Hypertension | 32 (26.7) | 19 (31.1) | 13 (22.0) | 0.26 |
| Diabetes | 10 (8.3) | 3 (4.9) | 7 (11.9) | 0.20 |
| Cardiac disease¶ | 7 (5.8) | 3 (4.9) | 4 (6.8) | 0.72 |
| Stroke | 3 (2.5) | 1 (1.6) | 2 (3.4) | 0.62 |
| COPD or asthma | 2 (1.6) | 2 (3.2) | 0 (0) | |
| Chronic renal insufficiency | 1 (0.8) | 0 | 1 (1.7) | |
| Malignancy | 7 (5.8) | 4 (6.6) | 3 (5.1) | 0.73 |
| Disease severity | 0.36 | |||
| General | 89 (74.2) | 48 (78.7) | 41 (69.5) | |
| Severe | 30 (25.0) | 13 (21.3) | 17 (28.8) | |
| Critical | 1 (0.8) | 0 (0) | 1 (1.7) | |
| Laboratory findings on admission+ | ||||
| White blood cell count ×109 cells·L−1 | 5.65 (4.14–7.33) | 0.57 | ||
| <4 | 27 (22.7) | 16 (26.7) | 11 (18.6) | |
| 4–10 | 82 (68.9) | 39 (65) | 43 (72.9) | |
| >10 | 10 (8.4) | 5 (8.3) | 5 (8.5) | |
| Lymphocyte count ×109 lymphocytes·L−1 | 1.14 (0.81–1.55) | |||
| <0.8 | 29 (24.3) | 18 (62.1) | 11 (37.9) | 0.15 |
| Platelet count ×109 platelets·L−1 | 195 (144–269) | |||
| <100 | 7 (5.9) | 5 (4.2) | 2 (1.0) | 0.44 |
| Creatinine level μmol·L−1 | 61 (52–74) | |||
| >133 | 4 (3.4) | 0 (0) | 4 (3.4) | |
| AST level U·L−1 | 31 (24–42.4) | |||
| >40 | 33 (27.7) | 14 (11.8) | 19 (16.0) | 0.18 |
| Treatment | ||||
| Corticosteroid therapy | 54 (45.0) | 28 (45.9) | 26 (44.1) | 0.78 |
| Lopinavir/ritonavir treatment | 78 (65) | 46 (75.4) | 33 (55.9) | 0.02 |
| Antibiotics | 102 (85.0) | 52 (85.2) | 50 (84.7) | 0.77 |
| High-flow nasal canula oxygen therapy | 21 (17.5) | 10 (16.4) | 11 (18.6) | 0.88 |
| Noninvasive mechanical ventilation | 2 (1.7) | 0 (0) | 2 (3.4) | |
| Invasive mechanical ventilation | 1 (0.8) | 0 (0) | 1 (1.7) | |
| Outcome | ||||
| Viral shedding days | 23 (18–32) | 18 (15–20.5) | 32 (28–38) | <0.001 |
| Symptom onset to temperature recovery days§ | 10 (6–15.5) | 7.5 (5–11) | 12 (8–20) | <0.001 |
| Symptom onset to radiological recovery days | 17 (12–21) | 13.5 (11–18) | 20 (12–24) | <0.001 |
| Hospital length of stay days | 21 (17–26) | 20 (15–24) | 22 (18–28) | 0.02 |
Data are presented as n, median (interquartile range) or n (%), unless otherwise stated. AST: aspartate aminotransferase. #: p-value represents comparisons between patients with prolonged viral shedding and those without; ¶: includes congestive heart disease and coronary atherosclerotic heart disease; +: data were available for 119 patients; §: data were from 99 patients.